$TTOO News
Last published 1y ago
- 1y agoTTOOT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireLEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced
- 1y agoTTOOT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorGlobeNewswireLEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four
- 1y agoTTOOT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyGlobeNewswireLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed
- 1y agoTTOOT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.GlobeNewswireLEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year
- 1y agoCAHTTOOT2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing PathogensGlobeNewswireLEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans
- 1y agoTTOOT2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTTOOT2 Biosystems Announces Third Quarter 2024 Financial ResultsGlobeNewswireLEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced
- 2y agoTTOOT2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024GlobeNewswireLEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report
- 2y agoTTOOT2 Biosystems, Inc. (TTOO) Business Update Conference Call TranscriptEarnings Call Transcripts
- 2y agoTTOOT2 Biosystems to Host Business Update Call on October 10, 2024GlobeNewswireLEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a
- 2y agoTTOOT2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support PlatformGlobeNewswireLEXINGTON, Mass. and SCHENECTADY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, and Prxcision,
- 2y agoCAHTTOOT2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing PathogensGlobeNewswireLEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that
- 2y agoTTOOT2 Biosystems Announces Preliminary Third Quarter 2024 Financial ResultsGlobeNewswireLEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited
- 2y agoTTOOT2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood CultureGlobeNewswireLEXINGTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a
- 2y agoTTOOT2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European UnionGlobeNewswireLEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that
- 2y agoTTOOT2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric PatientsGlobeNewswireLEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that
- 2y agoTTOOT2 Biosystems Provides Updates on its New Product Development Pipeline ProgressGlobeNewswireLEXINGTON, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today provided an
- 2y agoTTOOT2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireLEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate
- 2y agoTTOOT2 Biosystems to Attend Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate
- 2y agoTTOOT2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTTOOT2 Biosystems Announces Second Quarter 2024 Financial ResultsGlobeNewswireLEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced
- 2y agoTTOOT2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia DistributorGlobeNewswireLEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a
- 2y agoTTOOT2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024GlobeNewswireLEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report
- 2y agoPIRSTTOOFSTXAvacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of DirectorsGlobeNewswireAvacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company
- 2y agoTTOOT2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau DistributorGlobeNewswireLEXINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a
- 2y agoTTOOT2 Biosystems Regains Compliance with Nasdaq Continued Listing RequirementsGlobeNewswireLEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it
- 2y agoTTOOT2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswireLEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its
- 2y agoTTOOT2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswireLEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered
- 2y agoTTOOT2 Biosystems Announces CRG's Conversion from Preferred Stock to Common StockGlobeNewswireLEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that
- 2y agoTTOOT2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme DiseaseGlobeNewswireFiled Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2
- 2y agoTTOOT2 Biosystems, Inc. (TTOO) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTTOOT2 Biosystems Announces First Quarter 2024 Financial ResultsGlobeNewswireLEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced
- 2y agoTTOOT2 Biosystems Announces Commercial Expansion Through Middle East DistributorGlobeNewswireFiled Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2
- 2y agoTTOOT2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into EquityGlobeNewswireFiled Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2
- 2y agoTTOOT2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024GlobeNewswireLEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report
- 2y agoTTOOT2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityGlobeNewswireLEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the
- 2y agoTTOOT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.GlobeNewswireLEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year
- 2y agoTTOOT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesGlobeNewswireLEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans
- 2y agoTTOOT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesGlobeNewswireLEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that
- 2y agoTTOOT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelGlobeNewswireLEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the
- 2y agoTTOOT2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementGlobeNewswireLEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Nasdaq
- 2y agoTTOOT2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTTOOT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireLEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced
- 2y agoTTOOT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityGlobeNewswireLEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a
- 2y agoTTOOT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaGlobeNewswireLEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of
- 2y agoTTOOT2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria PanelGlobeNewswireLEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received
- 2y agoTTOOT2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024GlobeNewswireLEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report
- 2y agoTTOOU.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics PrizeGlobeNewswireLEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S.
- 2y agoTTOOT2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia PatientsGlobeNewswireLEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the
- 2y agoTTOOT2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric TestingGlobeNewswireLEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted